AdvaMed Women's Health Webinar Puts Clinical Representation and Investment on Medtech Agenda

AdvaMed used a 30 June webinar to put investment, product development and clinical representation in women's health on the medtech agenda, giving the sector a timely forum for what still needs to change in devices, diagnostics and health technology.

The event, Current Trends and Opportunities in Women's Health, ran from 1:00 PM to 2:00 PM on 30 June as part of AdvaMed's 2026 Women's Health Webinar Series. The series gathers members and the medtech industry to explore opportunities in women's health, with a focus on representation in clinical studies and investment in women's health companies and products.

That framing matters because women's health is often discussed as either a clinical access issue or a consumer wellness market. AdvaMed's event places it inside the business of medtech design, regulatory strategy, investment and evidence generation — covering innovation, recent developments, emerging opportunities, current challenges and the product development process from design through post-market.

For SheMeansNews readers, the practical significance is that women's health products do not become mainstream simply because demand exists. They need research budgets, trial design, regulatory pathways, payer interest, reimbursement strategy, manufacturing capacity, clinician adoption and investor patience. If women are underrepresented in clinical studies, or if products are designed around incomplete assumptions, the business case and the health outcome both weaken.

The webinar was moderated by Monika McDole-Russell, senior director of global regulatory intelligence and advertising/promotion at Intuitive — an experienced regulatory affairs executive who has led regulatory strategies for more than 25 medical devices. That detail is relevant because women's health innovation often gets stuck between promising science and the difficult work of getting a product safely through development and into real clinical use.

The business opportunity is not separate from the equity issue. When women-specific conditions are under-researched, companies may miss large markets and patients may wait longer for products that fit their needs. When women are properly represented in trials and product-design feedback, companies can reduce blind spots and build stronger evidence for adoption.

The 30 June webinar does not by itself change the capital gap in women's health. But it shows an influential medtech trade group treating the category as a serious industry conversation, not a side session. For founders, investors, regulatory leaders and clinicians, that is the opening needed to turn demand into better products and better-funded companies.